XLV — XLV | S&P 500 Health Care Sector ETF 13F holdings and portfolio analysis
Sign in to clone a new branch from the selected plan, then continue optimizing in the new branch.
Baseline
Analysis messagesPre-generated Q&A about this fund. Use as reference context for your own analysis.
Concentration is the first item to inspect: top 5 43.85%, top 10 59.80%, top 20 80.01%. The largest names are LLY (Eli Lilly and Company) 14.57%, JNJ (Johnson & Johnson) 10.34%, ABBV (AbbVie Inc.) 6.91%, UNH (UnitedHealth Group Incorporated) 6.67%, and MRK (Merck & Co., Inc.) 5.36%, and the largest sector exposures are Health Care 100.00%. If those exposures reverse, baseline performance can diverge sharply from a broad index.
The strongest recent period was 2025-10-31 (9.49% strategy return, 0.20% benchmark, 9.29% excess, 1.72% turnover), while the weakest was 2026-03-31 (-2.66% strategy return, 9.42% benchmark, -12.08% excess, 1.22% turnover). Those periods should be read alongside baseline metrics of return 8.14%, alpha -1.49%, beta 0.72, Sharpe 0.56, Sortino 0.74, and max drawdown -28.55% to judge whether returns came from persistent exposure or a narrow timing window.
The baseline is a direct read-through of the disclosed ETF or index-like fund. It is led by LLY (Eli Lilly and Company) 14.57%, JNJ (Johnson & Johnson) 10.34%, and ABBV (AbbVie Inc.) 6.91%, with sector exposure of Health Care 100.00%. The baseline metrics show return 8.14%, alpha -1.49%, beta 0.72, Sharpe 0.56, Sortino 0.74, and max drawdown -28.55%, so this should be treated as an equity exposure with its own concentration and timing risk rather than a neutral benchmark clone.